Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

US firm invests $16m in Indian blood cord banking and stem cell R&D project

This article was originally published in Clinica

  • News

Executive Summary

US firm StemCyte (Arcadia, California and Taiwan) has invested $16m in a public and private umbilical cord blood bank to be based in the Indian city of Ahmedabad. It will be co-owned by India's Apollo Hospital group (Chennai) and Cadila Pharmaceuticals (Ahmedabad), which will hold 26% each. StemCyte will double its initial investment in StemCyte Therapeutics India following the project's implementation, which is expected to be in 9-12 months. The company, which specialises in researching the therapeutic use of umbilical cord blood (UCB) stem cells, plans to use the centre in India to study the use of UCB stem cells to treat non-haematological conditions such as diabetes, stoke and liver disease.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

EU: Good News For IVDs And For Future Transparency Of Medtech Compliance

See All
UsernamePublicRestriction

Register

MT046340

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By